Skip to main content
SpringerLink
Log in

Radioiodine Therapy for Thyroid Cancer

  • Chapter
Thyroid Cancer

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Allweiss P, Braunstein GD, Kate A et al. (1984) Sialadenitis following I-131 therapy for thyroid cancer. J Nucl Med 25:755–758

    PubMed  Google Scholar 

  2. Al-Nahhas AM (1999) Ablation in differentiated thyroid carcinoma: How much surgery? How much iodine? [Editorial] Nucl Med Commun 20:595–597

    PubMed  Google Scholar 

  3. Arnstein NB, Carey JE, Spaulding SA et al. (1986) Determination of iodine-131 diagnostic dose for imaging metastatic thyroid cancer. J Nucl Med 27:1764–1769

    PubMed  Google Scholar 

  4. Beierwaltes WH (1978) The treatment of thyroid carcinoma with radioactive iodine. Semin Nucl Med 8:79–94

    PubMed  Google Scholar 

  5. Beierwaltes WH, Rabbani R, Dmuchowski C et al. (1984) An analysis of “ablation of thyroid remnants” with I-131 in 511 patients from 1947–1984: experience at University of Michigan. J Nucl Med 25:1287–1293

    PubMed  Google Scholar 

  6. Berg G, Lindstedt G, Suurküla M et al. (2002) Radioiodine ablation and therapy in differentiated thyroid cancer under stimulation with recombinant human thyroid-stimulating hormone. J Endocrinol Invest 25:44–52

    Google Scholar 

  7. Biersack HJ, Helpap B, Koch U et al. (1983) Should treatment of highly differentiated thyroid carcinoma be conservative? Nuklearmedizin 20:20–23

    Google Scholar 

  8. Börner AR, Petrich T, Weckesser E et al. (2002) Monitoring isotretinoin therapy in thyroid cancer using 18F-FDG PET. Eur J Nucl Med Mol Imaging 29:231–236

    Google Scholar 

  9. Bohuslavizki KH, Klutmann S, Brenner W et al. (1998) Salivary gland protection by ami-fostine in high-dose radioiodine treatment: result of a double-blind placebo-controlled study. J Clin Oncol 16:3542–3549

    PubMed  Google Scholar 

  10. Brown AP, Greening WP, McCready VR et al. (1984) Radioiodine treatment of metastatic thyroid carcinoma: the Royal Marsden Hospital experience. Br J Radiol 57:323–327

    PubMed  Google Scholar 

  11. Casara D, Rubello D, Saladini G et al. (1993) Different features of pulmonary metastases in differentiated thyroid cancer: natural history and multivariate statistical analysis of prognostic variables. J Nucl Med 34:1626–1631

    PubMed  Google Scholar 

  12. Casara D, Rubello D, Saladini G et al. (1993) Pregnancy after high therapeutic doses of iodine-131 in differentiated thyroid cancer: potential risks and recommendations. Eur J Nucl Med 20:192–194

    Article  PubMed  Google Scholar 

  13. Ceccarelli C, Battisti P, Gasperi M et al. (1999) Radiation dose to the testes after 131I therapy for ablation of postsurgical thyroid remnants in patients with differentiated thyroid cancer. J Nucl Med 40:1716–1721

    PubMed  Google Scholar 

  14. Chiu AC, Delpassand ES, Sherman SI (1997) Prognosis and treatment of brain metastases in thyroid carcinoma. J Clin Endocrinol Metab 82:3637–3642

    Article  PubMed  Google Scholar 

  15. Chopra S, Wastie ML, Chan S et al. (1996) Assessment of completeness of thyroid ablation by estimation of neck uptake of 131I on whole-body scans: comparison of quantification and visual assessment of thyroid bed uptake. Nucl Med Commun 17:687–691

    PubMed  Google Scholar 

  16. Comtois R, Theriault C, Del Vecchio P (1993) Assessment of the efficacy of iodine-131 for thyroid ablation. J Nucl Med 34:1927–1930

    PubMed  Google Scholar 

  17. Daumerie C, Vynckier S, Caussin J et al. (1996) Radioiodine treatment of thyroid carcinoma in patients on maintenance hemodialysis. Thyroid 6:301–304

    PubMed  Google Scholar 

  18. Dietlein M, Dressler J, Farahati J et al. (2004) Procedure Guidelines for radioiodine therapy of differentiated thyroid cancer (version 2) (in German). Nuklearmedizin 43:115–120

    PubMed  Google Scholar 

  19. Dottorini ME, Lomuscio G, Mazzucchelli L et al. (1995) Assessment of female fertility and carcinogenesis after I-131 therapy for differentiated thyroid carcinoma. J Nucl Med 36:21–27

    PubMed  Google Scholar 

  20. Edmonds CJ, Smith T (1986) The long-term hazards of the treatment of thyroid cancer with radioiodine. Br J Radiol 59:45–51

    PubMed  Google Scholar 

  21. Farahati J, Reiners C, Stuschke M et al. (1996) Differentiated thyroid cancer: impact of adjuvant external radiotherapy in patients with perithyroidal tumor infiltration (stage pT4). Cancer 77:172–180

    Article  PubMed  Google Scholar 

  22. Grüning T, Tiepolt C, Zöphel K, et al. (2003) Retinoic acid for redifferentiation of thyroid cancer — does it hold its promise? Eur J Endocrinol 148:395–402

    PubMed  Google Scholar 

  23. Grünwald F, Menzel C, Bender H et al. (1998) Redifferentiation therapy-induced radioiodine uptake in thyroid cancer. J Nucl Med 39:1903–1906

    PubMed  Google Scholar 

  24. Harbert JC (1987) Nuclear medicine therapy. Thieme, New York

    Google Scholar 

  25. Haugen BR (1999) Management of the patient with progressive radioiodine non-responsive disease. Semin Surg Oncol 16:34–41

    PubMed  Google Scholar 

  26. Haugen BR, Larson LL, Pugazhenthi U, et al. (2004) Retinoic acid and retinoid receptors are differentially expressed in thyroid cancer and thyroid carcinoma cell lines and predict response to treatment with retinoids. J Clin Endocrinol Metab 89:272–280

    PubMed  Google Scholar 

  27. Haugen BR, Pacini F, Reiners C et al. (1999) A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab 84: 3877–3885

    Article  PubMed  Google Scholar 

  28. Hay ID, Grant CS, van Heerden JA et al. (1992) Papillary thyroid microcarcinoma: a study of 535 cases observed in a 50-year period. Surgery 112:1139–1147

    PubMed  Google Scholar 

  29. Hedinger C, Williams ED, Sobin LH (1989) The WHO histological classification of thyroid tumors: a commentary on the second edition. Cancer 63:908–911

    PubMed  Google Scholar 

  30. Jarzab B, Handkiewicz-Junak D, Roskosz J, et al. (2003) Recombinant human TSH-aided radioiodine treatment of advanced differentiated thyroid carcinoma: a single-centre study of 54 patients. Eur J Nucl Med Mol Imaging 30:1077–1086

    Article  PubMed  Google Scholar 

  31. Jeevanram RK, Shah DH, Sharma M et al. (1986) Influence of initial large dose on subsequent uptake of therapeutic radioiodine in thyroid cancer patient. Nucl Med Biol 13:277–279

    Google Scholar 

  32. Keizer de B, Brans B, Hoekstra A, et al. (2003) Tumour dosimetry and response in patients with metastatic differentiated thyroid cancer using recombinant human thyrotropin before radioiodine therapy. Eur J Nucl Med Mol Imaging 30:367–373

    PubMed  Google Scholar 

  33. Kemmer W, Michalczak H (2003) Richtlinie Strahlenschutz in der Medizin 2002. Hildegard Hoffmann, Berlin

    Google Scholar 

  34. Ladenson PW, Braverman LE, Mazzaferri EL et al. (1997) Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma. N Engl J Med 337:888–896

    PubMed  Google Scholar 

  35. Lin JD, Chaa TC, Huang MJ et al. (1998) Use of radioactive iodine for thyroid remnant ablation in well differentiated thyroid carcinoma to replace thyroid re-operation. Am J Clin Oncol 21:77–81

    PubMed  Google Scholar 

  36. Lippi F, Capezzone M, Angelini F et al. (2001) Radioiodine treatment of metastatic differentiated thyroid cancer in patients on L-thyroxine, using recombinant human TSH. Eur J Endocrinol 144:5–11

    Article  PubMed  Google Scholar 

  37. Löffler M, Weckesser M, Franzius C et al. (2003) Iodine excretion during stimulation with rh TSH in differentiated thyroid carcinoma. Nuklearmedizin 42:240–243

    PubMed  Google Scholar 

  38. Lushbaugh CC, Casarett GW (1976) The effects of gonadal radiation in clinical radiation therapy. A review. Cancer 37:1111–1120

    PubMed  Google Scholar 

  39. Luster M, Lassmann M, Haenscheid H et al. (2000) Use of recombinant human thyrotropin before radioiodine therapy in patients with advanced differentiated thyroid carcinoma. J Clin Endocrinol Metab 85:3640–3645.

    Article  PubMed  Google Scholar 

  40. Maheshwari YK, Hill CS, Haynie TP et al. (1981) 131I therapy in differentiated thyroid carcinoma: M.D. Anderson Hospital experience. Cancer 47:664–671

    PubMed  Google Scholar 

  41. Maruca J, Santner S, Miller K et al. (1984) Prolonged iodine clearance with a depletion regimen for thyroid carcinoma. J Nucl Med 25:1089–1093

    PubMed  Google Scholar 

  42. Massin JP, Savoie JC, Garnier H et al. (1984) Pulmonary metastases in differentiated thyroid carcinoma. Cancer 53:982–992

    PubMed  Google Scholar 

  43. Maxon HR, Boehringer TA, Drilling J (1983) Low iodine diet in 1-131 ablation of thyroid remnants. Clin Nucl Med 8:123–126

    PubMed  Google Scholar 

  44. Maxon HR, Englaro EE, Thomas SR et al. (1992) Radioiodine-131 therapy for well-differentiated thyroid cancer — a quantitative radiation dosimetric approach: outcome and validation in 85 patients. J Nucl Med 33:1132–1136

    PubMed  Google Scholar 

  45. Maxon HR, Thomas SR, Hertzberg VS et al. (1983) Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer. N Engl J Med 309:937–941

    PubMed  Google Scholar 

  46. Mazzaferri EL (1995) Treating high thyroglobulin with radioiodine: a magic bullet or a shot in the dark? J Clin Endocrinol Metab 80:1485–1487

    Article  PubMed  Google Scholar 

  47. Mazzaferri EL (1996) Radioiodine and other treatments and outcomes. In: Braverman LE, Utiger RD (eds) The thyroid. Lippincott-Raven, Philadelphia, pp 922–945

    Google Scholar 

  48. Mazzaferri EL, Jhiang SM (1994) Long-term impact of initial surgery and medical therapy on papillary and follicular thyroid cancer. Am J Med 97:418–428

    Article  PubMed  Google Scholar 

  49. Mazzaferri EL, Robbins RJ, Spencer CA et al. (2003) A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab 88:1433–1441

    Article  PubMed  Google Scholar 

  50. Mazzaferri EL, Young E (1981) Papillary thyroid carcinoma: a 10-year follow-up report of the impact of therapy in 576 patients. Am J Med 70:511–518

    Article  PubMed  Google Scholar 

  51. McDougall IR (1997) 74 MBq radioiodine 131I does not prevent uptake of therapeutic doses of 131I (i.e. it does not cause stunning) in differentiated thyroid cancer. Nucl Med Commun 18:505–512

    PubMed  Google Scholar 

  52. Menzel C, Grünwald F, Schomburg A et al. (1996) “High-dose” radioiodine therapy in advanced differentiated thyroid carcinoma. J Nucl Med 37:1496–1503

    PubMed  Google Scholar 

  53. Morris JC, Kim CK, Padilla ML et al. (1997) Conversion of non-iodine-concentrating differentiated thyroid carcinoma metastases into iodine-concentrating foci after anticancer chemotherapy. Thyroid 7:63–66

    PubMed  Google Scholar 

  54. Moser E, Fritsch S, Braun S (1988) Thyroglobulin and 131 I uptake of remaining tissue in patients with differentiated carcinoma after thyroidectomy. Nucl Med Commun 9:262–266

    PubMed  Google Scholar 

  55. Nemec J, Zamrazil V, Pohunkova D et al. (1979) Radioiodine treatment of pulmonary metastases of differentiated thyroid cancer. Results and prognostic factors. Nuklearmedizin 18:86–90

    PubMed  Google Scholar 

  56. Nostrand van DV, Neutze J, Atkins F (1986) Side effects of “rational dose” iodine-131 therapy for metastatic well-differentiated thyroid carcinoma. J Nucl Med 27:1519–1527

    PubMed  Google Scholar 

  57. Pacini F, Gasperi M, Fugazzda L et al. (1994) Testicular function in patients with differentiated thyroid carcinoma treated with radioiodine. J Nucl Med 35:1418–1422

    PubMed  Google Scholar 

  58. Pacini F, Lippi F, Formica N et al. (1987) Therapeutic doses of iodine-131 reveal undiagnosed metastases in thyroid cancer patients with detectable serum thyroglobulin levels. J Nucl Med 28:1888–1891

    PubMed  Google Scholar 

  59. Pacini F, Molinaro E, Castagna MG et al. (2002) Ablation of thyroid residues with 30 mCi 131I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal. J Clin Endocrinol Metab 87:4063–4068

    Article  PubMed  Google Scholar 

  60. Park HM, Perkin OW, Edmondson JW et al. (1994) Influence of diagnostic radioiodines on the uptake of ablative dose of iodine-131. Thyroid 4:49–54

    PubMed  Google Scholar 

  61. Park JT II, Hennessey JV (2004) Two-week low iodine diet is necessary for adequate outpatient preparation for radioiodine rh TSH scanning in patients taking levothyroxine. Thyroid 14:57–63

    Article  PubMed  Google Scholar 

  62. Pellegriti G, Scollo C, Giuffrida D et al. (2001) Usefulness of recombinant human thyrotropin in the radiometabolic treatment of selected patients with thyroid cancer. Thyroid 11:1025–1030

    Article  PubMed  Google Scholar 

  63. Pineda JD, Lee T, Ain K et al. (1995) Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan. J Clin Endocrinol Metab 80:1488–1492

    Article  PubMed  Google Scholar 

  64. Pons F, Carrio I, Estorch M et al. (1987) Lithium as an adjuvant of iodine-131 uptake when treating patients with well-differentiated thyroid carcinoma. Clin Nucl Med 12:644–647

    PubMed  Google Scholar 

  65. Ramacciotti C, Pretorius HT, Line BR et al. (1982) Ablation of non-malignant thyroid remnants with low doses of radioiodine: concise communication. J Nucl Med 23:483–489

    PubMed  Google Scholar 

  66. Reiners C (1991) Stochastische Risiken der 1-131-Therapie des Schilddrüsenkarzinoms. Nuklearmediziner 20:331–334

    Google Scholar 

  67. Robbins J (1991) Thyroid cancer: a lethal endocrine neoplasm. Ann Intern Med 115:133–147

    PubMed  Google Scholar 

  68. Robbins RJ, Larson SM, Sinha N et al. (2002) A retrospective review of the effectiveness of recombinant human TSH as a preparation for radioiodine thyroid ablation. J Nucl Med 43:1482–1488

    PubMed  Google Scholar 

  69. Ronga G, Fiorentino A, Paserio E et al. (1990) Can iodine-131 whole body scan be replaced by thyroglobulin measurement in the postsurgical follow-up of differentiated thyroid carcinoma? J Nucl Med 31:1766–1771

    PubMed  Google Scholar 

  70. Rubino C, Vathaire F de, Dottorini ME et al. (2003) Second primary malignancies in thyroid cancer patients. Br J Cancer 89:1638–1644

    Article  PubMed  Google Scholar 

  71. Samaan NA, Schultz PN, Haynie TP et al. (1985) Pulmonary metastasis of differentiated thyroid carcinoma: treatment results in 101 patients. J Clin Endocrinol Metab 60:376–380

    PubMed  Google Scholar 

  72. Samaan NA, Schultz PN, Hickey R et al. (1992) The results of various modalities of treatment of well-differentiated thyroid carcinoma: a retrospective review of 1599 patients. J Clin Endocrinol Metab 75:714–720

    PubMed  Google Scholar 

  73. Sarkar SD, Beierwaltes WH, Gill SP et al. (1976) Subsequent fertility and birth histories of children and adolescents treated with 131I for thyroid cancer. J Nucl Med 17:460–464

    PubMed  Google Scholar 

  74. Schicha H, Dietlein M, Scheidhauer K (1999) Therapie mit offenen radioaktiven Stoffen. In: Büll U, Schicha H, Biersack HJ et al. (eds) Nuklearmedizin. Thieme, Stuttgart, pp 512–545

    Google Scholar 

  75. Schlumberger MJ (1998) Papillary and follicular thyroid carcinoma (review). N Engl J Med 338:297–306

    Article  PubMed  Google Scholar 

  76. Schlumberger M, Berg G, Cohen O et al. (2004) Follow-up of low-risk patients with differentiated thyroid carcinoma: a European perspective. Eur J Endocrinol 150:105–112

    Article  PubMed  Google Scholar 

  77. Schlumberger M, Challeton C, de Vathaire F et al. (1996) Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma. J Nucl Med 37:598–605

    PubMed  Google Scholar 

  78. Schlumberger M, de Vathaire F, Ceccarelli C et al. (1996) Exposure of radioactive iodine-131 for scintigraphy or therapy does not preclude pregnancy in thyroid cancer patients. J Nucl Med 37:606–612

    PubMed  Google Scholar 

  79. Schlumberger M, Tubiana M, De Vathaire F et al. (1986) Long-term results of treatment of 283 patients with lung and bone metastases from differentiated thyroid carcinoma. J Clin Endocrinol Metab 63:960–967

    PubMed  Google Scholar 

  80. Schober O, Günter HH, Schwarzrock R et al. (1987) Hämatologische Langzeitveränderungen bei der Radioiodtherapie des Schilddrüsenkarzinoms. I.) Periphere Blutbildveränderungen. Strahlenther Onkol 163:464–474

    PubMed  Google Scholar 

  81. Seabold JE, Ben-Haim S, Pettit WA et al. (1993) Diuretic-enhanced 1-131 clearance after ablation therapy for differentiated thyroid cancer. Radiology 187:839–842

    PubMed  Google Scholar 

  82. Simon D, Köhrle J, Schmutzler C et al. (1996) Redifferentiation therapy of differentiated thyroid carcinoma with retinoid acid: basics and first clinical results. Exp Clin Endocrinol Diabetes 104[Suppl 4]:13–15

    PubMed  Google Scholar 

  83. Simon D, Köhber C, Krausch M et al. (2002) Clinical impact of retinoids in redifferentiation therapy of advanced thyroid cancer: final results of a pilot study. Eur J Nucl Med Mol Imaging 29:775–782

    Article  PubMed  Google Scholar 

  84. Sisson JC, Jamadar DA, Kazerooni EA et al. (1998) Treatment of micronodular lung metastases of papillary thyroid cancer: are the tumors too small for effective irradiation from radioiodine? Thyroid 8:215–221

    PubMed  Google Scholar 

  85. Solans R, Bosch J-A, Galofré P et al. (2001) Salivary and lacrimal gland dysfunction (sicca syndrome) after radioiodine therapy. J Nucl Med 42:738–743

    PubMed  Google Scholar 

  86. Solomon BL, Wartowsky L, Burman KD (1996) Current trends in the management of well differentiated papillary thyroid carcinoma. J Clin Endocrinol Metab 81:333–339

    Article  PubMed  Google Scholar 

  87. Spiegel W, Reiners C, Börner W (1985) Sialadenitis following iodine-131 therapy for thyroid carcinoma [letter]. J Nucl Med 26:816

    PubMed  Google Scholar 

  88. Strahlenschutzkommission (2004) Notwendigkeit der stationären Durchführung der Ganzkörperszintigraphie mit 1-131 beim Schilddrüsenkarzinom. Empfehlung der Strahlenschutzkommission. Verabschiedet in der 190. Sitzung der Strahlenschutzkommission am 22/23. April 2004

    Google Scholar 

  89. Strahlenschutzverordnung 2001 (2002) Bundesanzeiger, Köln

    Google Scholar 

  90. Sweeney DC, Johnston GS (1995) Radioiodine therapy for thyroid cancer. Endocrinol Metabol Clin North Am 24:803–839

    Google Scholar 

  91. Travagli JP, Cailleux AF, Ricard M et al. (1998) Combination of radioiodine (131I) and probe-guided surgery for persistent or recurrent thyroid carcinoma. J Clin Endocrinol Metab 83:2675–2680

    Article  PubMed  Google Scholar 

  92. Varma VM, Beierwaltes WH, Nofal MM et al. (1970) Treatment of thyroid cancer: death rates after surgery and after surgery followed by sodium iodine 1-131. JAMA 214:1437–1442

    Article  PubMed  Google Scholar 

  93. Varma VM, Dai WL, Henkin RI (1992) Taste dysfunction in patients with thyroid cancer following treatment with 1-131. J Nucl Med 33:996

    Google Scholar 

  94. Wittekind C, Meyer JH, Bootz F (2003) TNM Klassifikation maligner Tumoren. 6. Aufl. Springer, Berlin Heidelberg New York

    Google Scholar 

  95. Wong JB, Kaplan MM, Meyer KB et al. (1990) Ablative radioactive iodine therapy for apparently localized thyroid carcinoma. A decision analytic perspective. Endocrinol Metab Clin North Am 19:741–760

    PubMed  Google Scholar 

  96. Zettinig G, Hanselmayer G, Fueger BJ et al. (2002) Long-term impairment of the lacrimal glands after radioiodine therapy: a cross-sectional study. Eur J Nucl Med Mol Imaging 29:1428–1432

    Article  PubMed  Google Scholar 

Download references

Authors
  1. M. Dietlein
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D. Moka
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H. Schicha
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Klinik und Poliklinik für Nuklearmedizin, Rheinische Friedrich-Wilhelms-Universität, Sigmund-Freud-Strasse 25, 53127, Bonn, Germany

    H.-J. Biersack (Professor Dr. med.) (Professor Dr. med.)

  2. Klinik für Nuklearmedizin, Universität Frankfurt, Theodor-Stern-Kai 7, 60590, Frankfurt am Main, Germany

    F. Grünwald (Professor Dr. med.) (Professor Dr. med.)

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Dietlein, M., Moka, D., Schicha, H. (2005). Radioiodine Therapy for Thyroid Cancer. In: Biersack, HJ., Grünwald, F. (eds) Thyroid Cancer. Springer, Berlin, Heidelberg. https://doi.org/10.1007/3-540-27845-1_6

Download citation

  • DOI: https://doi.org/10.1007/3-540-27845-1_6

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-22309-2

  • Online ISBN: 978-3-540-27845-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation